Sign up
Pharma Capital

'We have a shot at being a multi-billion dollar company', says VentriPoint Diagnostic's George Adams

Dr George Adams, CEO & president of VentriPoint Diagnostics (CVE:VPT) runs Proactive through the company's heart analysis technology and growth strategy as well as plans for 2017.

 

View full VPT profile

VentriPoint Diagnostics Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.